Get started

Hypergrowth

SoFi: A Catalyst Saturated Fintech About To Drive Rapid GrowthSoFi has been beaten down, manipulated and ridiculed due to its SPAC origins… without even taking into perspective of the fast growth ahead of it. The biggest reason that SoFi hasn’t seen rapid growth so far is due to the Biden Administration Extending Student Loan Pause Through May 1, 2022. I firmly expect this to be the last extension. “The Department will continue its work to transition borrowers smoothly back into repayment…” When this ends in combination with SoFi recently getting its bank charter approved… Revenue and Profit Projections will be updated to the positive. SoFi has already started rolling out new features for members such as Margin trading, a 1.00% APY on both checking and savings (Market Leading) APY). More to come… I highly expect SoFi’s upcoming earnings to be solid with an incredibly positive guidance ahead of it. Many Major Analysts support this outlook with current ratings and price targets. My Opinion: $25+ is very realistic within the short term (2-4 months) $35-$45 by end of the year with continued expansion in provided products as well as operations through CONUS & Internationally. (Not a licensed financial advisor)
NASDAQ:SOFILong
by AlexCutler247
Can SAVA get back to $100 in the short term? $SAVA (Cassava Sciences) saw an insane rally in 2021 from $7 to $145 on the hopes that its groundbreaking Alzheimer's treatment will yield promising results never before seen in the history of the disease. Currently there are no Alzheimer's modifying therapies on the market and if the data surrounding Cassava's main drug, simufilam, is accurate then it could be the first of its kind. SAVA saw a sell-the-news event when it announced its promising results, suffering a 23% drop on July 29. Soon thereafter a Stat News article was released criticizing Cassava's results, citing a group of independent researchers. The stock dropped a total of 55% from highs. Is this a buying opportunity? Obviously we are largely delving in uncharted territory and financial analysts/traders won't be able to infer whether the science is reliable or not. However, traders know how market cycles largely work. There is often a second wave of optimism after negative news coverage (whether a short report or a hit piece), driven by those who are willing to speculate. SAVA is showing a bullish harami on the 1D and it has dropped to the Fibonacci golden pocket level, also at the 100 MA where it has routinely found support. This could be a buying opportunity for those who are in the market for a bit of risk. As long as #SAVA is above the 100 MA, I'm willing to hold it in the mid term and will ride the next wave of positive financial/medical news. Entry: $79 SL: soft SL with manual monitoring if it breaches the 100 MA TP: $88, $94, $100
NASDAQ:SAVALong
by TheTravel1ngTrader
Potential IPO base $LMNDPotential IPO base "90 seconds to get insured. 3 minutes to get paid" If you haven't already noticed, we are living in a world of immediate gratification. Insurance is just another sector that's ripe to be disrupted by better efficiency. TA, - Increasing volume and consolidating at previous highs $69. FA, - Disrupting the archaic industry of insurance -High NPS score of 70. Industry average is 70. - $5 Trillion TAM. Current market cap is $3.8Bn - Huge barrier between insurance companies and customers. Making claims is a headache. Lemonade is bridging that gap through better customer service by leveraging the powers of AI. AI JIM and AI MAYA - +167% revenue growth 2020 - Expansion beyond US. France is next by end of 2020. - Only 3 types available still. Renters, home and pet insurance. More potential for other types Concerns, - Still not fully convinced of the business model -Continued losses(side effect of disrupting) - Price discovery phase still so will be super volatile. Entry : Break of 69.2 Stop loss: 62.2
NYSE:LMNDLong
by ashainp